Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GERON CORPORATION

(GERN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Geron : to Announce First Quarter 2021 Financial Results on May 10, 2021

05/03/2021 | 04:35pm EDT

Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2021 financial results after the market closes on Monday, May 10, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the conference call live via telephone by pre-registering online using the following link, http://www.directeventreg.com/registration/event/2456438. Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.


© Business Wire 2021
All news about GERON CORPORATION
09/16GERON : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
09/14GERON : R.W. Baird Global Healthcare Conference
PU
09/13GERON : HC Wainwright Healthcare Conference
PU
09/01GERON : Announces September Investor Conference Presentation Webcasts
BU
08/19GERON : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16GERON : Second Quarter 2021 Conference Call
PU
08/16GERON : Logs Wider Q2 Loss as Revenue Rises, Sees Myelodysplasia Trial Fully Enr..
MT
08/16GERON CORP : Results of Operations and Financial Condition, Financial Statements..
AQ
08/16GERON : Reports Greater Than 90% Enrollment in IMerge Phase 3 andExpected Top-Li..
PU
08/16GERON : Q2 Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2021 0,35 M - -
Net income 2021 -117 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,96x
Yield 2021 -
Capitalization 452 M 452 M -
Capi. / Sales 2021 1 278x
Capi. / Sales 2022 1 884x
Nbr of Employees 54
Free-Float 99,8%
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,41 $
Average target price 4,20 $
Spread / Average Target 198%
EPS Revisions
Managers and Directors
John A. Scarlett Chairman, President & Chief Executive Officer
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Aleksandra Rizo Chief Medical Officer & Executive Vice President
Andrew J. Grethlein Chief Operating Officer & Executive Vice President
Karin Eastham Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GERON CORPORATION-10.69%452
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850